Startup entity
Of the tracked stories, 2 of 2 also mention Ben Lamm, the most common co-covered peer. Across a 140-day span, the pace is roughly 0.1 stories per week. They are better corroborated than the beat average, carrying 3 original sources each against 2.9 for the same window.
Last mentioned: Jul 21, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Ben Lamm, the most common co-covered peer. Across a 140-day span, the pace is roughly 0.1 stories per week. They are better corroborated than the beat average, carrying 3 original sources each against 2.9 for the same window. The 7.5 average consequence score is above the beat benchmark of 6.7 in the same window. The clearest coverage concentration is funding: 1 of 2 stories, with the rest divided among 1 other category. This profile follows 2 Startup stories mentioning Colossal Biosciences across the period from March 4, 2026 to July 21, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 1162 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Colossal Biosciences. Shared-story counts are live from our verified record — not editorial picks.
Venture capital’s most audacious bet, Colossal Biosciences, is seeking a valuation of $20–$30 billion — a nearly 3x jump — as it generates revenue, spins out high-value startups, and turns its de-extinction mission into a startup factory with government clients and AI-driven assets.
Colossal Biosciences is advancing its mission to revive the woolly mammoth by 2028, sparking intense debate over the ethics of de-extinction. While the startup has secured over $225 million in venture capital, critics argue the project is a costly distraction from urgent conservation efforts for living species.
Colossal Biosciences is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
